The endogenous cannabinoid system modulates nicotine reward and dependence

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 2, 2008, Pages 483-492

  Merritt, Lisa L ^a   Martin, B R ^a   Walters, C ^a   Lichtman, A H ^a   Damaj, M Imad ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; MECAMYLAMINE; NICOTINE; RIMONABANT;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE DELETION; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; CONDITIONING (PSYCHOLOGY); ENDOCANNABINOIDS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NICOTINE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; REWARD; SIGNAL TRANSDUCTION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 47949097194     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.138321     Document Type: Article

References (40)

1. Alexander JP and Cravatt BF (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179-1187.
2. Balerio GN, Aso E, Berrendero F, Murtra P, and Maldonado R (2004) Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 20:2737-2748.
3. Butt C, Alptekin A, Shippenberg T, and Oz M (2008) Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem 105:1235-1243.
4. Castañé A, Berrendero F, and Maldonado R (2005) The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav 81:381-386.
5. Castañé A, Valjent E, Ledent C, Parmentier M, Maldonado R, and Valverde O (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43:857-867.
6. Cheer JF, Wassum KM, Heien ML, Phillips PE, and Wightman RM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24:4393-4400.
7. Cohen C, Kodas E, and Griebel G (2005a) CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81:387-395.
8. Cohen C, Perrault G, Griebel G, and Soubrie P (2005b) Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30:145-155.
9. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98:9371-9376.
10. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
11. Cravatt BF and Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475.
12. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
13. Damaj MI, Kao W, and Martin BR (2003) Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307:526-534.
14. Damaj MI, Siu EC, Sellers EM, Tyndale RF, and Martin BR (2007) Inhibition of nicotine metabolism by methoxysalen: pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320:250-257.
15. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
16. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, and Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358.
17. GonzálezS, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, and Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81.
18. Grabus SD, Martin BR, Brown SE, and Damaj MI (2006) Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) 184:456-463.
19. Hutchinson E, Avery A, and Vandewoude S (2005) Environmental enrichment for laboratory rodents. ILAR J 46:148-161.
20. Jackson KJ, Martin BR, Changeux JP, and Damaj MI (2008) Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther 325:302-312.
21. Le Foll B and Goldberg SR (2004) Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15:2139-2143.
22. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, and Cravatt BF (2004a) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448.
23. Lichtman AH, Shelton CC, Advani T, and Cravatt BF (2004b) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109:319-327.
24. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, et al. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54:1-7.
25. Moreira FA, Kaiser N, Monory K, and Lutz B (2008) Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54:141-150.
26. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, and Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21-38.
27. Reinhardt V (2004) Common husbandry-related variables in biomedical research with animals. Lab Anim 38:213-235.
28. Risinger FO and Oakes RA (1995) Nicotine-induced conditioned place preference and conditioned place aversion in mice. Pharmacol Biochem Behav 51:457-461.
29. Rodríguez de FonsecaF, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, and Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14.
30. Simon GM and Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem 281:26465- 26472.
31. Solinas M, Justinova Z, Goldberg SR, and Tanda G (2006) Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 98:408-419.
32. Spivak CE, Lupica CR, and Oz M (2006) The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 72:1024-1032.
33. Suzuki T, Ise Y, Tsuda M, Maeda J, and Misawa M (1996) Mecamylamine-precipitated nicotine-withdrawal aversion in rats. Eur J Pharmacol 314:281-284.
34. Valjent E, Mitchell JM, Besson MJ, Caboche J, and Maldonado R (2002) Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135:564-578.
35. Varvel SA, Wise LE, Niyuhire F, Cravatt BF, and Lichtman AH (2007) Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 32:1032-1041.
36. Walters CL, Brown S, Changeux JP, Martin B, and Damaj MI (2006) The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology (Berl) 184:339-344.
37. Wise LE, Shelton CC, Cravatt BF, Martin BR, and Lichtman AH (2007) Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur J Pharmacol 557:44-48.
38. Wonnacott S, Irons J, Rapier C, Thorne B, and Lunt GG (1989) Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 79:157-163.
39. Wonnacott S, Sidhpura N, and Balfour DJ (2005) Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 5:53-59.
40. Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, Lannoye GS, Richardson P, Stewart A, Rogers JC, et al. (2007) Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52:1095-1105.